Friday, July 10, 2026

pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA

Iovance Biotherapeutics

Iovance Biotherapeutics is a pharma organization headquartered in San Carlos, USA. It trades on NYSE under ticker IOVA. Primary therapeutic focus areas include Metastatic Melanoma, Unresectable Melanoma, Metastatic Non-S

825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
Status
Public
HQ
825 Industrial Rd, Suite 400, San Carlos, California 94070, US
Founded
2007
Employees
916
Programs
36
Drugs
26
Patents
94
Clinical program

C-145-04

Phase 2 · small molecule · Recurrent, metastatic, or persistent Cervical Carcinoma

C-145-04 for Recurrent, metastatic, or persistent Cervical Carcinoma is a Phase 2 program (small_molecule) at Iovance Biotherapeutics B.V. with 1 ClinicalTrials.gov record(s).

Internal code C-145-04

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Iovance Biotherapeutics B.V.
Phase
Phase 2
Modality
small_molecule
Indication
Recurrent, metastatic, or persistent Cervical Carcinoma
Status
active
Trials
1